A Phase 1 interventional study of BI 705564 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-07.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to investigate safety and tolerability of BI 705564 in healthy male subjects, following oral administration of multiple rising doses.
Secondary objectives are the exploration of the pharmacokinetics, including dose proportionality and investigation of linearity.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
DG 8, only: Otherwise healthy male subjects (as defined for DGs 1 to 5) with a history (of at least 1 year) of IgE-mediated, perennial allergies, predominantly to (house) dust mite (dermatophagoides pteronyssinus or dermatophagoides farina) as documented by a positive Skin prick test (SPT)(largest diameter of wheal at screening > 5 mm)
Exclusion Criteria:
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 705564
Drug: BI 705564 · Drug: Midazolam
Drug: BI 705564 · Drug: Midazolam
Drug: BI 705564 · Drug: Midazolam
Drug: BI 705564 · Drug: Midazolam
Drug: Placebo · Drug: Midazolam
SPT stands for skin prick test.
Drug: BI 705564
SPT stands for skin prick test.
Drug: Placebo
Percentage of Participants With Drug-related Adverse Events
Percentage of participants with drug-related adverse events is reported.
Time frame: From first drug administration until 10 days after last drug administration, up to 27 days (for dose groups 1 to 5 and "Placebo Matching BI 705564") or up to 37 days (for dose group 8 and "Placebo Matching BI 705564 - SPT").
Area Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1)
Area under the concentration-time curve of BI 705564 in plasma over a uniform dosing interval τ after administration of the first dose of BI 705564 (AUCτ,1) is reported. Here AUCτ,1 = AUC0-24.
Time frame: 1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).
Maximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose
Maximum measured concentration of BI 705564 in plasma (Cmax) after the administration of the first dose of BI 705564 is reported.
Time frame: 1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).
Area Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose
Area under the concentration-time curve of BI 705564 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after the administration of the last dose of BI 705564 is reported. As per the protocol, day is counted as "Day 1 = 0:00".
Time frame: 1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).
Maximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose
Maximum measured concentration of BI 705564 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after the administration of the last dose. As per the protocol, day is counted as "Day 1 = 0:00".
Time frame: 1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) After the First and Last Dose
Area under the concentration-time curve of Midazolam in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.
Time frame: 1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.
Maximum Measured Concentration of Midazolam in Plasma (Cmax) After the First and Last Dose
Maximum measured concentration of Midazolam in plasma (Cmax) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.
Time frame: 1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.
The evaluation of multiple rising dose (MRD) of BI 705564 was designed as randomised, placebo-controlled, double-blind and parallel-group design and the evaluation of midazolam interaction was designed as nested, open-label, fixed-sequence, intra-individual comparison in healthy male participants.
| Milestone | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 2 | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 10 | 2 | 8 | 8 | 6 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Percentage of participants with drug-related adverse events is reported.
| Percentage of participants (%) | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Drug-related Adverse Events | 20.0 | 50.0 | 12.5 | 0.0 | 50.0 | 50.0 | 12.5 | 75.0 |
Area under the concentration-time curve of BI 705564 in plasma over a uniform dosing interval τ after administration of the first dose of BI 705564 (AUCτ,1) is reported. Here AUCτ,1 = AUC0-24.
| nanomole*hour/liter (nmol*h/L) | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1) | 42.1 ± 40.6 | 70.8 ± 31.7 | 131.0 ± 22.4 | 168.0 ± 40.1 | 238.0 ± 46.6 | 120.0 ± 33.9 |
Maximum measured concentration of BI 705564 in plasma (Cmax) after the administration of the first dose of BI 705564 is reported.
| nanomole/Liter (nmol/L) | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose | 11.4 ± 42.2 | 18.8 ± 38.2 | 36.5 ± 17.8 | 41.0 ± 28.1 | 58.1 ± 54.4 | 31.7 ± 35.2 |
Area under the concentration-time curve of BI 705564 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after the administration of the last dose of BI 705564 is reported. As per the protocol, day is counted as "Day 1 = 0:00".
| nanomole *hour/liter (nmol*h/L) | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose | 45.9 ± 34.2 | 84.8 ± 25.9 | 164.0 ± 34.3 | 170.0 ± 62.1 | 204.0 ± 179.0 | 138.0 ± 32.1 |
Maximum measured concentration of BI 705564 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after the administration of the last dose. As per the protocol, day is counted as "Day 1 = 0:00".
| nanomole/Liter (nmol/L) | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose | 13.3 ± 29.4 | 19.8 ± 23.7 | 41.8 ± 21.4 | 43.4 ± 57.2 | 52.6 ± 201.0 | 39.2 ± 28.3 |
Area under the concentration-time curve of Midazolam in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.
| picomole*hour/Liter (pmol*h/L) | Placebo Matching BI 705564 | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg |
|---|---|---|---|---|---|
| After last dose: Midazolam + BI705564 or Midazolam + Placebo (Treatment (T)) | 4478.58 ± NA | 3463.24 ± NA | 4812.45 ± NA | 3458.32 ± NA | 3759.20 ± NA |
| After first dose: Midazolam alone (Reference (R)) | 4356.03 ± NA | 3721.70 ± NA | 4382.24 ± NA | 3191.16 ± NA | 3445.42 ± NA |
Maximum measured concentration of Midazolam in plasma (Cmax) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.
| picomole/Liter (pmol/L) | Placebo Matching BI 705564 | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg |
|---|---|---|---|---|---|
| After last dose: Midazolam +BI 705564 or Midazolam +Placebo (Treatment (T)) | 1197.89 ± NA | 1040.42 ± NA | 1255.36 ± NA | 984.14 ± NA | 1058.32 ± NA |
| After first dose: Midazolam alone (Reference (R)) | 1196.63 ± NA | 1232.26 ± NA | 1147.40 ± NA | 1031.18 ± NA | 1175.41 ± NA |
Collected over From first drug administration until 10 days after last drug administration, up to 27 days (for dose groups 1 to 5 and "Placebo Matching BI 705564" ) or up to 37 days (for dose group 8 and "Placebo Matching BI 705564 - SPT").. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching BI 705564 | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Placebo Matching BI 705564 - SPT | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Dose Group 1: BI 705564 10 mg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Dose Group 2: BI 705564 20 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Dose Group 3: BI 705564 40 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Dose Group 5: BI 705564 60 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Dose Group 4: BI 705564 80 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Dose Group 8: BI 705564 40 mg - SPT | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT |
|---|---|---|---|---|---|---|---|---|
| PalpitationsCardiac disorders | 0/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| FatigueGeneral disorders | 1/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 2/8 |
| NasopharyngitisInfections and infestations | 1/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 2/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 1/2 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| Limb discomfortMusculoskeletal and connective tissue disorders | 0/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Musculoskeletal discomfortMusculoskeletal and connective tissue disorders | 0/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Spinal painMusculoskeletal and connective tissue disorders | 0/10 | 1/2 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 0/10 | 1/2 | 2/8 | 0/8 | 1/8 | 0/8 | 0/8 | 4/8 |
Treated Set (TS): This subject set includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(Years) | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.1 ± 8.2 | 33.0 ± 2.8 | 34.8 ± 9.6 | 44.0 ± 5.7 | 32.3 ± 9.1 | 38.4 ± 8.3 | 40.5 ± 10.2 | 28.5 ± 10.7 | 36.9 ± 9.7 |
| Sex: Female, Male(Participants) | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 10 | 2 | 8 | 8 | 8 | 8 | 8 | 8 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 2 | 8 | 8 | 8 | 8 | 8 | 8 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching BI 705564 | Placebo Matching BI 705564 - SPT | Dose Group 1: BI 705564 10 mg | Dose Group 2: BI 705564 20 mg | Dose Group 3: BI 705564 40 mg | Dose Group 5: BI 705564 60 mg | Dose Group 4: BI 705564 80 mg | Dose Group 8: BI 705564 40 mg - SPT | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| White | 10 | 1 | 7 | 8 | 8 | 7 | 7 | 7 | 55 |
| More than one race | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Nov 2018, 12 months.
Results were first posted in Jul 2022, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BI 705564 · Midazolam